
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma Inc. is showing a positive outlook due to promising preclinical data for its drug candidates, particularly STRO-004, which demonstrated significant improvements in safety and anti-tumor activity compared to existing therapies. The company's strategic decision to reduce its workforce by approximately 50% aims to streamline operations and is expected to lead to a substantial decrease in operating expenses, projected to decline by 50-70% starting in the second quarter of 2025. Additionally, the ongoing development of innovative products such as STRO-006, which possesses enhanced safety and efficacy characteristics, positions the company favorably in a competitive market, highlighting its commitment to advancing its biopharmaceutical pipeline.
Bears say
Sutro Biopharma faces significant risks that could impair its financial performance, particularly if the clinical results for its lead antibody-drug conjugate candidates fall short of expectations, leading to decreased market penetration and elongated approval timelines. The fiscal year 2024 registered a net loss of $227.4 million, corresponding to a loss of $2.96 per share, while cash reserves decreased to $316.9 million from $388.3 million within three months, indicating potential liquidity concerns. Additionally, management's decision to implement a nearly 50% reduction in workforce and discontinue its lead luvelta program reflects a strategic retreat that may negatively impact future growth prospects and investor confidence.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares